Form
Fill Out The Form To Begin Your Download
Conjugation of polyethylene glycol (PEG) to therapeutic molecules can increase drug half-life, solubility, and therapeutic potency. However, an increasing number of healthy individuals develop anti-PEG antibodies. PEG immunogenicity can cause anaphylactic shock and dramatically reduce the efficacy of the treatment. Find out about our polysarcosine (pSar) alternative to PEG by downloading the document.
Support for Your Therapeutic Program
Contact a Chemist Today
Contact Us, and we can discuss your specific therapeutic program and how Curapath can help build the right solution to advance your unique drug.